<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00747461</url>
  </required_header>
  <id_info>
    <org_study_id>15-00026</org_study_id>
    <nct_id>NCT00747461</nct_id>
  </id_info>
  <brief_title>Interventional Cryotherapy for the Eradication of Benign Airway Disease (&quot;ICE the BAD&quot;)</brief_title>
  <acronym>ICEtheBAD</acronym>
  <official_title>Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease(&quot;ICE THE BAD&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSA Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSA Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, effectiveness, and side effects of the
      CryoSpray AblationTM System (CryoSpray AblationTM, &quot;CSA&quot; or &quot;cryospray therapy&quot;) to treat
      benign airway disease in the lung using liquid nitrogen sprayed through a catheter via
      flexible fiber optic bronchoscopy (FFB)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a single center pilot study consisting of up to 10 subjects with benign
      airway disease. Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will
      have initial cryospray treatment at Day 0. Subjects will undergo repeat bronchoscopy in the
      first three to seven days after the initial treatment, to check for mucosal sloughing and to
      reassess luminal patency of the airway. Subjects may undergo up to one bronchoscopy per week
      with CSA therapy for a total of four (4) treatments in the first month. If they present with
      symptoms thereafter, then a repeat bronchoscopy will be performed; if luminal obstruction is
      noted, then the subject will begin the treatment protocol again. If disease exists
      bilaterally, only one side will be sprayed initially.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Reasons
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Luminal Patency Following Cryospray Treatment</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Durability</measure>
    <time_frame>12 months</time_frame>
    <description>need for additional treatments within specified period</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Lung Diseases, Obstructive</condition>
  <condition>Sarcoidosis</condition>
  <condition>Wegener's Granulomatosis</condition>
  <condition>Rhinoscleroma</condition>
  <condition>Recurrent Respiratory Papillomatosis</condition>
  <arm_group>
    <arm_group_label>Cryospray Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental CSA (Cryospray Ablation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CryoSpray Ablation</intervention_name>
    <description>Cryospray Ablation up to 4 -5 second cycles for up to 4 treatments in the first 30 days</description>
    <arm_group_label>Cryospray Ablation</arm_group_label>
    <other_name>CryoSpray Ablation(TM)System</other_name>
    <other_name>Cryotherapy</other_name>
    <other_name>Cryosurgery</other_name>
    <other_name>Cryospray</other_name>
    <other_name>Cryo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age

          -  Deemed a candidate for cryotherapy based on physician physical or medical history
             review

          -  Deemed operable based on institutional criteria.

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Planning to sire a child while enrolled in the study

          -  Known history of unresolved drug or alcohol dependency that would limit ability to
             comprehend or follow instructions related to informed consent, post-treatment
             instructions, or follow-up guidelines.

          -  Refusal or inability to give consent.

          -  Concurrent chemotherapy.

          -  Prior radiation therapy which involved the any area between the vocal chords and the
             diaphragm

          -  Medical contraindication or potential problem that would preclude study participation

          -  Concurrent participation in other experimental studies Uncontrolled coagulopathy or
             bleeding diathesis

        Serious medical illness, including:

          -  Uncontrolled congestive heart failure

          -  Uncontrolled angina

          -  Myocardial infarction

          -  Cerebrovascular accident within 6 months prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Machuzak, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.csamedical.com</url>
    <description>Click here for more information about CryoSpray Ablation and this study.</description>
  </link>
  <reference>
    <citation>Johnston MH, Eastone JA, Horwhat JD, Cartledge J, Mathews JS, Foggy JR. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc. 2005 Dec;62(6):842-8.</citation>
    <PMID>16301023</PMID>
  </reference>
  <reference>
    <citation>Johnston CM, Schoenfeld LP, Mysore JV, Dubois A. Endoscopic spray cryotherapy: a new technique for mucosal ablation in the esophagus. Gastrointest Endosc. 1999 Jul;50(1):86-92.</citation>
    <PMID>10385730</PMID>
  </reference>
  <reference>
    <citation>Ell C, May A, Gossner L, Pech O, Günter E, Mayer G, Henrich R, Vieth M, Müller H, Seitz G, Stolte M. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology. 2000 Apr;118(4):670-7.</citation>
    <PMID>10734018</PMID>
  </reference>
  <reference>
    <citation>Champion G, Richter JE, Vaezi MF, Singh S, Alexander R. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology. 1994 Sep;107(3):747-54.</citation>
    <PMID>8076761</PMID>
  </reference>
  <reference>
    <citation>Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol. 1997 Jan;92(1):27-31.</citation>
    <PMID>8995932</PMID>
  </reference>
  <reference>
    <citation>Johnston MH. Cryotherapy and other newer techniques. Gastrointest Endosc Clin N Am. 2003 Jul;13(3):491-504. Review.</citation>
    <PMID>14629105</PMID>
  </reference>
  <reference>
    <citation>Cash BD, Johnston LR, Johnston MH. Cryospray ablation (CSA) in the palliative treatment of squamous cell carcinoma of the esophagus. World J Surg Oncol. 2007 Mar 16;5:34.</citation>
    <PMID>17367523</PMID>
  </reference>
  <reference>
    <citation>Field JK, Youngson JH. The Liverpool Lung Project: a molecular epidemiological study of early lung cancer detection. Eur Respir J. 2002 Aug;20(2):464-79.</citation>
    <PMID>12212983</PMID>
  </reference>
  <reference>
    <citation>Pinsonneault C, Fortier J, Donati F. Tracheal resection and reconstruction. Can J Anaesth. 1999 May;46(5 Pt 1):439-55. Review.</citation>
    <PMID>10349923</PMID>
  </reference>
  <reference>
    <citation>Dumot JA. Cryotherapy Ablation for Esophageal HGD or IMCA in High Risk, Non-Surgical Patients. DDW2007 Abstract submission. Cleveland Clinic Foundation (pending publication)</citation>
  </reference>
  <reference>
    <citation>Greenwald BD. CryoSpray Ablation of Early Esophageal Cancer. DDW 2007 Abstract submission. University of Maryland Medical Center. (pending publication)</citation>
  </reference>
  <reference>
    <citation>Johnston M, Horwhat J, Dubois A, Schoenfeld P. Endoscopic cryotherapy in the swine esophagus: A follow-up study (Abstract). Gastrointestinal Endoscopy 49:AB126, 1999.</citation>
  </reference>
  <reference>
    <citation>Johnston MH, Horwhat JD, Haluska, Moses FM. Depth of injury following endoscopic spray cryotherapy: EUS assisted evaluation of mucosal ablation and subsequent healing in the swine model (Abstract). Gastrointestinal Endoscopy 51: AB98, 3462, 2000.</citation>
  </reference>
  <reference>
    <citation>Johnston MH. Endoscopic cryotherapy: A new ice age in gastroenterology? Medscape Gastroenterology 2: 187, 2000.</citation>
  </reference>
  <reference>
    <citation>Eastone JA, Horwhat D, Haluska O, Mathews J, Johnston M. Cryoablation of swine esophageal mucosa: A direct comparison to argon plasma coagulation (APC) and multipolar electrocoagulation (MPEC) [Abstract] Gastrointestinal Endoscopy 53: A3448, 2001.</citation>
  </reference>
  <reference>
    <citation>Johnston MH, Eastone JA, Horwhat JD. Reversal of Barrett's esophagus with cryotherapy [Abstract]. American Journal of Gastroenterology 98(9 Suppl): A30, S11, 2003.</citation>
  </reference>
  <reference>
    <citation>Johnston MH, Cash BD, Horwhat JD, Johnston LR, Dykes CA, Mays HS. Cryoablation of Barrett's Esophagus (BE) [Abstract]. Gastroenterology 130 (4, Suppl.2): A640, 2006.</citation>
  </reference>
  <reference>
    <citation>Johnston MH, Cash BD, Dykes CA, Mays HS, Johnston LR. Cryoablation of dysplasia in Barrett's Esophagus (BE) and early stage esophageal cancer [Abstract]. Gastrointestinal Endoscopy 63 (5): April, 2006.</citation>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2008</study_first_submitted>
  <study_first_submitted_qc>September 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2008</study_first_posted>
  <results_first_submitted>June 4, 2015</results_first_submitted>
  <results_first_submitted_qc>June 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 26, 2015</results_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benign Airway Disease</keyword>
  <keyword>Airway Injury</keyword>
  <keyword>Sarcoidosis</keyword>
  <keyword>Wegener's Granulomatosis</keyword>
  <keyword>Rhinoscleroma</keyword>
  <keyword>Recurrent Respiratory Papillomatosis(RRP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Rhinoscleroma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cryo Spray Ablation</title>
          <description>subjects receiving up to 4 -5 second spray cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cryo Spray Ablation</title>
          <description>subjects will receive up to 4 -5 second cycles of cryospray ablation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Luminal Patency Following Cryospray Treatment</title>
        <time_frame>30 days</time_frame>
        <population>study terminated by Sponsor-data not analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Cryo Spray Ablation</title>
            <description>Subject receiving cryo spray ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Luminal Patency Following Cryospray Treatment</title>
          <population>study terminated by Sponsor-data not analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Durability</title>
        <description>need for additional treatments within specified period</description>
        <time_frame>12 months</time_frame>
        <population>study terminated-no subjects analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cryo Spray Ablation</title>
            <description>subjects receiving cryo spray ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Durability</title>
          <description>need for additional treatments within specified period</description>
          <population>study terminated-no subjects analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Subjects Receiving CSA Cryospray</title>
          <description>All subjects enrolled will received CSA cryospray.
CryoSpray Ablation (tm): The CryoSpray Ablation(TM) System is a cryosurgical device utilizing a low-pressure liquid nitrogen spray tip CSATM Catheter. Medical grade liquid nitrogen is the cryogen used in the device. The device is used to destroy unwanted tissue by the application of extreme cold with the focused application to select tissue. The cryogen is stored in a liquid nitrogen holding tank integrated into the system.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ann Murphy Legg, Director of Clinical Research</name_or_title>
      <organization>CSA Medical</organization>
      <phone>781-538-4732</phone>
      <email>alegg@csamedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

